First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
ICI plus Chemothearpy: This intervention involves the administration of immune checkpoint inhibitors (ICIs) in combination with standard chemotherapy.
Chemotherapy: This intervention involves the administration of standard chemotherapy alone.
Study summary
This prospective observational study aims to evaluate the efficacy and safety of immune checkpoint inhibitors as first-line and neoadjuvant therapy for advanced gastric cancer, while also investigating relevant biomarkers to better understand their role in immunotherapy outcomes
Eligibility
Primary outcome measure(s)
- Overall survival (OS) — 12 months after the last subject participating in
The time from the starting date of study drug to death
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Qilu Hospital of Shandong University | Jinan | Shandong | Recruiting |
More Qilu Hospital of Shandong University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06727981 on ClinicalTrials.gov ↗ ← All trials in China